Tolerability of riluzole in an open-label phase IIIb study;Tolérance du riluzole dans un essai ouvert (phase IIIb)

Therapie

Volumn 57, Issue 1, 2002, Pages 65-71

  Lacomblez, L ^a   Dib, M ^b   Doppler, V ^a   Faudet, A ^a   Robin, V ^b   Salachas, F ^a   Bensimon, G ^a   Meininger, V ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SANOFI   (France)

Author keywords

ALS; Riluzole; Tolerance

Indexed keywords

AMINOTRANSFERASE; RILUZOLE;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASTHENIA; CLINICAL TRIAL; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL;

AGED; AMYOTROPHIC LATERAL SCLEROSIS; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PRODUCT SURVEILLANCE, POSTMARKETING; RILUZOLE;

EID: 0036262405     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Adult onset motor neuron disease: Worldwide mortality, incidence and distribution since 1950
2. A controlled trial of riluzole in amyotrophic lateral sclerosis
3. Meininger V for the Amyotrophic Lateral Sclerosis/Riluzole Study group II. Dose-ranging study of riluzole in amyotrophic lateral sclerosis
4. German open label trial of riluzole 50 mg b.i.d. in treatment of amyotrophic lateral sclerosis (ALS)
5. The riluzole early access programme: Descriptive analysis of 844 patients in France
6. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis
7. Riluzole
8. A confirmatory dose-ranging study of riluzole in ALS
9. Onset, natural history and outcome in idiopathic adult motor neuron disease
10. The natural history of amyotrophic lateral sclerosis
11. Reversible granulocytopenia in association with riluzole therapy
12. Adverse effects of riluzole (Rilutek) in the treatment of amyotrophic lateral sclerosis